Page contentsPage contents Key facts Decision Related medicine information Key facts Invented name Xalkori Active substance crizotinib Therapeutic area Oncology Decision number P/0361/2018 PIP number EMEA-001493-PIP02-18 Pharmaceutical form(s) Capsule, hard Condition(s) / indication(s) Treatment of lung malignant neoplasms Route(s) of administration Oral use Contact for public enquiries Pfizer Europe MA EEIG Tel. +44 (0)1304 646 607E-mail: pip_enquiries@pfizer.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 07/12/2018 Compliance check done No Decision P/0361/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for crizotinib (Xalkori), (EMEA-001493-PIP02-18)Adopted Reference Number: EMA/762548/2018 English (EN) (126.02 KB - PDF)First published: 20/02/2019 View Related medicine information Xalkori Share this page